Tubulis closes Series C round for 344 million euros
The Munich-based biotech company Tubulis has successfully closed its Series C financing round with a total volume of 344 million euros (401 million US dollars). The second and final tranche brings new investors on board, including Fidelity Management & Research Company, Janus Henderson Investors and Blackstone Multi-Asset Investing.
The round was led by Venrock Healthcare Capital Partners, with participation from Wellington Management, Ascenta Capital and existing investors such as EQT Life Sciences, Nextech Invest, Frazier Life Sciences, Andera Partners, Bayern Kapital, HTGF and other institutional investors.
Capital for clinical trials and pipeline development
Tubulis intends to use the new funds to significantly accelerate its clinical programs, in particular the further development of the ADC drug candidate TUB-040, which is being investigated in ovarian cancer. Following promising clinical results presented at the ESMO 2025 Congress in Berlin, TUB-040 will now be tested in pivotal studies.
With this funding, we are in a strong position to achieve our goal of realizing the full potential of ADC therapies for more patients.
Dr. Dominik Schumacher, CEO and co-founder of Tubulis
In addition, the company plans to explore earlier stage treatments and combination therapies as well as address new solid tumor indications. In parallel, the development of the second clinical ADC candidate TUB-030 and several preclinical programs will be advanced.
ADC technology as the next generation of cancer medicine
Tubulis is one of the leading European developers of antibody-drug conjugates (ADCs). This is a class of cancer drugs that combines the targeting precision of antibodies with the efficacy of cytotoxic substances.
With its proprietary platform technologies, including the Tubutecan technology, the company is able to generate ADCs with high stability, targeted tumor release and an improved safety profile. Initial clinical data of TUB-040 in platinum-resistant ovarian cancer show strong antitumor activity even at low doses and good tolerability.
The new investors underline the international confidence in Tubulis' leading role in ADC development. With the Series C financing, the company is now one of the best capitalized private biotech companies in Europe.
Antibody-Drug Conjugates on the rise
ADC therapies are currently one of the most dynamic fields of research in oncology. They combine targeted antibodies with highly effective active substances and thus enable more precise, more effective and more tolerable cancer therapies. With the ongoing development of its own platform technologies, Tubulis aims to further optimize the ADC modality and open up new applications beyond traditional tumor therapy. We have already reported on the first closing for Tubulis.
FYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?
